Simplified Admix Archaeal Glycolipid Adjuvanted Vaccine and Checkpoint Inhibitor Therapy Combination Enhances Protection from Murine Melanoma
Authors:
- Felicity C. StarkFSFelicity C. Stark
- Gerard AgbayaniGAGerard Agbayani
- Jagdeep K. SandhuJSJagdeep K. Sandhu
- Bassel AkacheBABassel Akache
- Charis McPhersonCMCharis McPherson
- Lise DeschateletsLDLise Deschatelets
- Renu DudaniRDRenu Dudani
- Melissa HewittMHMelissa Hewitt
- Yimei JiaYJYimei Jia
- Lakshmi KrishnanLKLakshmi Krishnan
- Michael J. McCluskieMMMichael J. McCluskie
Open Access
- 23 November 2019
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 7 (4) , 91
Abstract
Archaeosomes are liposomes composed of natural or synthetic archaeal lipids that when used as adjuvants induce strong long-lasting humoral and cell-mediated immune responses against entrapped antigens. However, traditional entrapped archaeosome formulations have only low entrapment efficiency, therefore we have developed a novel admixed formulation which offers many advantages, including reduced loss of antigen, consistency of batch-to-batch production as well as providing the option to formulate the vaccine immediately before use, which is beneficial for next generation cancer therapy platforms that include patient specific neo-antigens or for use with antigens that are less stable. Herein, we demonstrate that, when used in combination with anti-CTLA-4 and anti-PD-1 checkpoint therapy, this novel admixed archaeosome formulation, comprised of preformed sulfated lactosyl archaeol (SLA) archaeosomes admixed with OVA antigen (SLA–OVA (adm)), was as effective at inducing strong CD8+ T cell responses and protection from a B16-OVA melanoma tumor challenge as the traditionally formulated archaeosomes with encapsulated OVA protein. Furthermore, archaeosome vaccine formulations combined with anti-CTLA-4 and anti-PD-1 therapy, induced OVA-CD8+ T cells within the tumor and immunohistochemical analysis revealed the presence of CD8+ T cells associated with dying or dead tumor cells as well as within or around tumor blood vessels. Overall, archaeosomes constitute an attractive option for use with combinatorial checkpoint inhibitor cancer therapy platforms.Keywords
This publication has 44 references indexed in Scilit:
- Archaeosomes display immunoadjuvant potential for a vaccine against Chagas diseaseHuman Vaccines & Immunotherapeutics, 2013
- Synthetic Archaeosome Vaccines Containing Triglycosylarchaeols Can Provide Additive and Long-Lasting Immune Responses That Are Enhanced by ArchaetidylserineArchaea, 2012
- Tumor-Infiltrating Lymphocyte Grade Is an Independent Predictor of Sentinel Lymph Node Status and Survival in Patients With Cutaneous MelanomaJournal of Clinical Oncology, 2012
- The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 2012
- RD Antigen Based Nanovaccine Imparts Long Term Protection by Inducing Memory Response against Experimental Murine TuberculosisPLOS ONE, 2011
- Archaeosome Adjuvant Overcomes Tolerance to Tumor‐Associated Melanoma Antigens Inducing Protective CD8+ T Cell ResponsesJournal of Immunology Research, 2010
- Development of new glycosylation methodologies for the synthesis of archaeal-derived glycolipid adjuvantsCarbohydrate Research, 2010
- Archaeobacterial Ether Lipid Liposomes as Vaccine Adjuvants2003
- Tumours can act as adjuvants for humoral immunityImmunology, 2001
- Archaeosome Vaccine Adjuvants Induce Strong Humoral, Cell-Mediated, and Memory Responses: Comparison to Conventional Liposomes and AlumInfection and Immunity, 2000